| Pharmaceutical Information |
| Drug Name |
Mitoxantrone |
| Drug ID |
BADD_D01480 |
| Description |
An anthracenedione-derived antineoplastic agent. |
| Indications and Usage |
For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis |
| Marketing Status |
approved; investigational |
| ATC Code |
L01DB07 |
| DrugBank ID |
DB01204
|
| KEGG ID |
D08224
|
| MeSH ID |
D008942
|
| PubChem ID |
4212
|
| TTD Drug ID |
D0R3JB
|
| NDC Product Code |
61703-343 |
| UNII |
BZ114NVM5P
|
| Synonyms |
Mitoxantrone | Mitozantrone | DHAQ | NSC-279836 | NSC 279836 | NSC279836 | NSC-287836 | NSC 287836 | NSC287836 | NSC-299195 | NSC 299195 | NSC299195 | NSC-301739 | NSC 301739 | NSC301739 | NSC-301739D | NSC 301739D | NSC301739D | Mitroxone | Pralifan | CL-232325 | CL 232325 | CL232325 | Mitoxantrone Acetate | Acetate, Mitoxantrone | Mitoxantrone Hydrochloride | Hydrochloride, Mitoxantrone | Novantrone | Ralenova | Novantron | Onkotrone |
|
| Chemical Information |
| Molecular Formula |
C22H28N4O6 |
| CAS Registry Number |
65271-80-9 |
| SMILES |
C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
